Page 42«..1020..40414243

ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

By Dr. Matthew Watson

ORIC-114 is a potential best-in-class inhibitor designed for brain penetrance and selectivity for exon 20 insertion mutations of EGFR and HER2

Originally posted here:
ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program

To Read More: ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program
categoriaGlobal News Feed commentoComments Off on ORIC Pharmaceuticals Expands Precision Oncology Pipeline with Exclusive License to Brain Penetrant EGFR/HER2 Exon 20 Inhibitor Program | dataOctober 19th, 2020
Read All

Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

By Dr. Matthew Watson

MALVERN, Pa., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders, today announced that it plans to release third quarter 2020 financial and operating results after market close on Monday, November 2, 2020. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day.

Read the rest here:
Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call

To Read More: Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call
categoriaGlobal News Feed commentoComments Off on Neuronetics to Report Third Quarter 2020 Financial and Operating Results and Host Conference Call | dataOctober 19th, 2020
Read All

Replimune Appoints Tanya Lewis to the Board of Directors

By Dr. Matthew Watson

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of November 2, 2020.

Read the original post:
Replimune Appoints Tanya Lewis to the Board of Directors

To Read More: Replimune Appoints Tanya Lewis to the Board of Directors
categoriaGlobal News Feed commentoComments Off on Replimune Appoints Tanya Lewis to the Board of Directors | dataOctober 19th, 2020
Read All

Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

By Dr. Matthew Watson

EMERYVILLE, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Berkeley Lights, Inc. (Nasdaq: BLI), a leader in Digital Cell Biology, today announced the company will be report financial results for the third quarter 2020 after market close on Thursday, November 12, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

See more here:
Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020

To Read More: Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020
categoriaGlobal News Feed commentoComments Off on Berkeley Lights Announces Webcast of Third Quarter Financial Results on November 12, 2020 | dataOctober 19th, 2020
Read All

UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

View post:
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on UPDATE — Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

By Dr. Matthew Watson

John Sperzel will serve on the Industry Council of the Advisory Board John Sperzel will serve on the Industry Council of the Advisory Board

Continued here:
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member

To Read More: Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
categoriaGlobal News Feed commentoComments Off on Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member | dataOctober 19th, 2020
Read All

Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

By Dr. Matthew Watson

Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies Data presentations to cover both SURE-1 and SURE-2 urinary tract infection studies

Originally posted here:
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020

To Read More: Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020 | dataOctober 19th, 2020
Read All

First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

By Dr. Matthew Watson

TORONTO, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today it has dosed the first patient in the Phase II trial of its lead drug LSALT peptide, targeting prevention of acute lung injury, acute kidney injury and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

Go here to see the original:
First Patient Dosed in Phase II Trial to Treat Complications in COVID-19

To Read More: First Patient Dosed in Phase II Trial to Treat Complications in COVID-19
categoriaGlobal News Feed commentoComments Off on First Patient Dosed in Phase II Trial to Treat Complications in COVID-19 | dataOctober 17th, 2020
Read All

Theratechnologies Appoints Two New Board Members

By Dr. Matthew Watson

MONTREAL, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Mr. Andrew Molson and Mr. Alain Trudeau as new independent members to its Board of Directors.

Continued here:
Theratechnologies Appoints Two New Board Members

To Read More: Theratechnologies Appoints Two New Board Members
categoriaGlobal News Feed commentoComments Off on Theratechnologies Appoints Two New Board Members | dataOctober 17th, 2020
Read All

Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

By Dr. Matthew Watson

Originally posted here:
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol

To Read More: Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol
categoriaGlobal News Feed commentoComments Off on Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol | dataOctober 17th, 2020
Read All

Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

By Dr. Matthew Watson

SOUTH ORANGE, NJ, Oct. 16, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Nephros, Inc. (Nasdaq: NEPH) (“Nephros” or the “Company”), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical device and commercial markets, today announced the pricing of a registered direct offering of 833,333 shares of common stock at a price to the public of $6.00 per share.  The offering is expected to close on or about October 20, 2020, subject to the satisfaction of customary closing conditions.

Link:
Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock

To Read More: Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock
categoriaGlobal News Feed commentoComments Off on Nephros Announces Pricing of $5 Million Registered Direct Offering of Common Stock | dataOctober 17th, 2020
Read All

Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

By Dr. Matthew Watson

MALVERN, Pa., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases, today announced that Cantor Fitzgerald and Kristen Kluska will host a Management Fireside Chat Zoom Call on October 21 at 11 a.m. ET.

See the original post here:
Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen

To Read More: Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen
categoriaGlobal News Feed commentoComments Off on Cantor Fitzgerald and Kristen Kluska to Host Zoom Fireside Chat with Ocugen | dataOctober 17th, 2020
Read All

Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

By Dr. Matthew Watson

GARDEN CITY, N.Y., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced new in vitro and in vivo preclinical data that suggest the Company’s innovative gNO-based treatment may treat lung cancer locally and its metastases systemically, potentially via stimulation of an anti-tumor immune response. These data were included in a presentation by Hila Confino, PhD of Beyond Air at the International Association for the Study of Lung Cancer’s (IASLC) North America Conference on Lung Cancer 2020 (NACLC 2020), which is being held from October 16th to 17th.

Read the original:
Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination

To Read More: Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination
categoriaGlobal News Feed commentoComments Off on Beyond Air® Presents Positive New Preclinical Data for the Use of a Single Injection of Gaseous Nitric Oxide as a Novel In situ Cancer Vaccination | dataOctober 17th, 2020
Read All

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

By Dr. Matthew Watson

CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

Link:
CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis

To Read More: CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis
categoriaGlobal News Feed commentoComments Off on CHMP recommends approval of Dupixent® (dupilumab) for children aged 6 to 11 years with severe atopic dermatitis | dataOctober 17th, 2020
Read All

Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

By Dr. Matthew Watson

Final European Commission Decision on Marketing Approval Anticipated in Q4 2020 Final European Commission Decision on Marketing Approval Anticipated in Q4 2020

Continued here:
Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe

To Read More: Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe
categoriaGlobal News Feed commentoComments Off on Aimmune Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe | dataOctober 17th, 2020
Read All

Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

By Dr. Matthew Watson

15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial

View original post here:
Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

To Read More: Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020
categoriaGlobal News Feed commentoComments Off on Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020 | dataOctober 17th, 2020
Read All

Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

By Dr. Matthew Watson

EMERYVILLE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced that the Committee for Medicinal Products for Human Use (CHMP), a part of the European Medicines Agency (EMA), has adopted a positive opinion recommending the marketing authorization of FINTEPLA® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome, a rare and devastating infant- and childhood onset epilepsy, as an add-on therapy to other antiepileptic medicines for patients two years of age and older. The European Commission (EC) is expected to make a final decision on the company’s Marketing Authorization Application (MAA) by the end of the year.

Read this article:
Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome

To Read More: Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome
categoriaGlobal News Feed commentoComments Off on Zogenix Receives Positive CHMP Opinion for FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Patients with Dravet Syndrome | dataOctober 17th, 2020
Read All

SPACs Show Investors Faster, Simpler Way to Go Public

By Dr. Matthew Watson

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- 180 Life Sciences Corp. announces the availability of a broadcast titled, “Blockbuster Year and Bright Horizons for SPACs.”

See original here:
SPACs Show Investors Faster, Simpler Way to Go Public

To Read More: SPACs Show Investors Faster, Simpler Way to Go Public
categoriaGlobal News Feed commentoComments Off on SPACs Show Investors Faster, Simpler Way to Go Public | dataOctober 17th, 2020
Read All

Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential

By Dr. Matthew Watson

NEW YORK, Oct. 16, 2020 (GLOBE NEWSWIRE) -- NetworkNewsAudio -- Cybin Corp. announces the availability of a broadcast titled, “Multi-Billion-Dollar Market Forecast in Psychedelic Therapeutics.”

Read more here:
Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential

To Read More: Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential
categoriaGlobal News Feed commentoComments Off on Psychedelics Experiencing Renaissance, Offer Tremendous Treatment Potential | dataOctober 17th, 2020
Read All

Biomerica Reports Fiscal 2021 1st Quarter Financial Results

By Dr. Matthew Watson

IRVINE, Calif., Oct. 16, 2020 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), a global provider of advanced medical products, today reported financial results for the fiscal quarter ended August 31, 2020.

See more here:
Biomerica Reports Fiscal 2021 1st Quarter Financial Results

To Read More: Biomerica Reports Fiscal 2021 1st Quarter Financial Results
categoriaGlobal News Feed commentoComments Off on Biomerica Reports Fiscal 2021 1st Quarter Financial Results | dataOctober 17th, 2020
Read All

Page 42«..1020..40414243